BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 11602729)

  • 1. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    Zwick MB; Labrijn AF; Wang M; Spenlehauer C; Saphire EO; Binley JM; Moore JP; Stiegler G; Katinger H; Burton DR; Parren PW
    J Virol; 2001 Nov; 75(22):10892-905. PubMed ID: 11602729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
    J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
    J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
    Huarte N; Lorizate M; Maeso R; Kunert R; Arranz R; Valpuesta JM; Nieva JL
    J Virol; 2008 Sep; 82(18):8986-96. PubMed ID: 18596094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
    Zhang MY; Vu BK; Choudhary A; Lu H; Humbert M; Ong H; Alam M; Ruprecht RM; Quinnan G; Jiang S; Montefiori DC; Mascola JR; Broder CC; Haynes BF; Dimitrov DS
    J Virol; 2008 Jul; 82(14):6869-79. PubMed ID: 18480433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
    Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
    Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1757-65. PubMed ID: 11788027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
    Shen X; Parks RJ; Montefiori DC; Kirchherr JL; Keele BF; Decker JM; Blattner WA; Gao F; Weinhold KJ; Hicks CB; Greenberg ML; Hahn BH; Shaw GM; Haynes BF; Tomaras GD
    J Virol; 2009 Apr; 83(8):3617-25. PubMed ID: 19193787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HIV gp41-specific antibodies that mediate killing of infected cells.
    Williams KL; Stumpf M; Naiman NE; Ding S; Garrett M; Gobillot T; Vézina D; Dusenbury K; Ramadoss NS; Basom R; Kim PS; Finzi A; Overbaugh J
    PLoS Pathog; 2019 Feb; 15(2):e1007572. PubMed ID: 30779811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J; Wyatt RT
    PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress towards the development of a HIV-1 gp41-directed vaccine.
    McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
    Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
    Shen X; Dennison SM; Liu P; Gao F; Jaeger F; Montefiori DC; Verkoczy L; Haynes BF; Alam SM; Tomaras GD
    Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5972-7. PubMed ID: 20231447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
    Alam SM; Scearce RM; Parks RJ; Plonk K; Plonk SG; Sutherland LL; Gorny MK; Zolla-Pazner S; Vanleeuwen S; Moody MA; Xia SM; Montefiori DC; Tomaras GD; Weinhold KJ; Karim SA; Hicks CB; Liao HX; Robinson J; Shaw GM; Haynes BF
    J Virol; 2008 Jan; 82(1):115-25. PubMed ID: 17942537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
    Yang G; Holl TM; Liu Y; Li Y; Lu X; Nicely NI; Kepler TB; Alam SM; Liao HX; Cain DW; Spicer L; VandeBerg JL; Haynes BF; Kelsoe G
    J Exp Med; 2013 Feb; 210(2):241-56. PubMed ID: 23359068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions.
    Rathinakumar R; Dutta M; Zhu P; Johnson WE; Roux KH
    J Virol; 2012 Feb; 86(3):1820-31. PubMed ID: 22090143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
    Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
    Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.